Gst-hg121 has selected PCC, or become a new target of hepatitis B treatment in the world
-
Last Update: 2019-06-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Guangshengtang announced on June 24 that it has selected preclinical candidate compounds (PCC) for its global innovative drug gst-hg121 project of hepatitis B treatment, which is in the preparation stage before the ind application (clinical registration application) In vitro and animal efficacy tests showed that gst-hg121 was a HBsAg inhibitor with significant efficacy, excellent safety and global intellectual property rights Gst-hg121 can play a role by degrading RNA, and greatly improve the negative rate of HBsAg, which is expected to become a new target of hepatitis B treatment in the world The original announcement is as follows:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
